The winners and losers of Biden’s plans to expand coverage of weight-loss drugs US President Joe Biden wants to expand the ...

Concerns have been raised by senior doctors surrounding the misuse of weight-loss pens in the UK, with some patients reporting extreme side effects. | ITV National News ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. Currently, there are four ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Eli Lilly and Company chief corporate brand officer Lina Polimeni described the new format as a “big evolution” in the ...

Erste Group downgraded Eli Lilly (LLY) to Hold from Buy.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...